Trademarkia Logo

Canada

C$
Trademark Search in Canada
AI-POWR

View On IC.GC.CA

AI-POWR
ABANDONED SECTION 36

on 25 Jul 2023

Last Applicant/ Owned by

HEPION PHARMACEUTICALS INC.

399 Thornall Street, 1st FloorEdison NJ 08837

US

Serial Number

2116176 filed on 29th Dec 2020

AI-POWR

Trademark usage description

computer software for using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, stat Read More

Classification Information

Class [009]
Computer software for using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation in clinical trials or studies, designing clinical trials or studies, enriching and enhancing clinical trial or study designs, de-risking clinical trial or study designs, clinical trials simulations, clinical endpoint selection, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses, patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field; computer software for integrating artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation with disease studies and investigations, pharmaceutical and drug research and development, biomedical, biological, and biotechnological research and development, and pharmacology, clinical pharmacology, system pharmacology, and system biology; computer software for clinical trials or studies, designing clinical trials or studies, enriching and enhancing clinical trial or study designs, de-risking clinical trial or study designs, clinical trials simulations, clinical endpoint selection, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation; computer software for patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation; computer software for drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, accessing, processing, and analyzing public and proprietary omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data via a global computer network using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation; computer software for disease studies and investigations, understanding of diseases, pharmaceutical and drug research and development, biomedical, biological, and biotechnological research and development, and pharmacology, clinical pharmacology, system pharmacology, system biology research and development using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation.

Classification kind code

11

Class [042]
Design, development, programming, testing, maintenance, customization, and operation of computer software in clinical trials or studies, designing clinical trials or studies, enriching and enhancing clinical trial or study designs, de-risking clinical trial or study designs, clinical trials simulations, clinical endpoint selection, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses, patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation; consulting, consultancy, and consulting services related to clinical trials or studies, designing clinical trials or studies, enriching and enhancing clinical trial or study designs, de-risking clinical trial or study designs, clinical trials simulations, clinical endpoint selection, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses, patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and related to the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); platform as a service (PaaS) featuring computer platforms and software for using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation in clinical trials or studies, designing clinical trials or studies, enriching and enhancing clinical trial or study designs, de-risking clinical trial or study designs, clinical trials simulations, clinical endpoint selection, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses, patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field; software as a service (SaaS) featuring computer platforms for using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation in clinical trials or studies, designing clinical trials or studies, enriching and enhancing clinical trial or study designs, de-risking clinical trial or study designs, clinical trials simulations, clinical endpoint selection, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses, patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field; research and development in clinical trials or studies, designing clinical trials or studies, enriching and enhancing clinical trial or study designs, de-risking clinical trial or study designs, clinical trials simulations, clinical endpoint selection, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses, patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation; performing clinical trials or studies, designing clinical trials or studies, enriching and enhancing clinical trial or study designs, de-risking clinical trial or study designs, clinical trials simulations, clinical endpoint selection, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses, patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and services in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation for others (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations).

Classification kind code

11

Class [044]
Medical and veterinary, beauty, agricultural and forestry

Comment text

CIPO Classification Code

Classification kind code

Nice

Mark Details

Serial Number

2116176

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 14
on 2th May 2023		Default Notice Sent
Submitted for opposition 22
on 11th Oct 2022		Search Recorded
Submitted for opposition 20
on 11th Oct 2022		Examiner's First Report
Submitted for opposition 223
on 11th Oct 2022		Total Provisional Refusal
Submitted for opposition 256
on 25th Apr 2022		Notification of Possible Opposition Sent
Submitted for opposition 257
on 24th Jun 2021		Designation Notification - Madrid Protocol
Submitted for opposition 1
on 23rd Jun 2021		Created
Submitted for opposition 31
on 23rd Jun 2021		Formalized
Submitted for opposition 30
on 29th Dec 2020		Filed
Submitted for opposition 228
on 29th Dec 2020		International Registration